Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) presented multiple studies at the American Society for Microbiology's Microbe conference from June 9-13, 2022. Key focus areas included sulbactam-durlobactam (SUL-DUR) for multidrug-resistant Acinetobacter infections and ETX0462, a novel PBP inhibitor targeting Gram-negative bacteria. Oral and poster presentations detailed pharmacodynamics, in vitro activities, and the drug's efficacy against resistant strains, showcasing Entasis's commitment to addressing urgent antimicrobial resistance challenges.
- Presentation of promising data on sulbactam-durlobactam targeting MDR Acinetobacter infections.
- Research on ETX0462 indicates broad-spectrum antimicrobial activity against Gram-negative bacteria.
- None.
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum antimicrobial activity against MDR Gram-negative bacteria, including Pseudomonas aeruginosa.
Details of the presentations are as follows:
Sulbactam-Durlobactam
Oral Presentations:
Sulbactam-durlobactam (SUL-DUR), a targeted β-lactam/β-lactamase inhibitor, for MDR Acinetobacter infections
Presenter: Alita A. Miller; June 10 8:15am; Salon GHI
Pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex (ABC)
Presenter: John O’Donnell; June 11 3:00pm; Salon C
Poster Presentations (Poster Hall):
#3114: In vitro activity of sulbactam-durlobactam against recent clinical Acinetobacter baumannii-calcoaceticus complex isolates from the United States
June 10
Presenter: Alita A. Miller
#3473: In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii clinical isolates collected in 2020 from China
June 10
Presenter: Sarah M. McLeod
#3490: Potent activity of sulbactam-durlobactam against pan-drug resistant Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent 5-year surveillance study (2016-2020)
June 10
Presenter: Sarah M. McLeod
#2776: In vitro activity of sulbactam-durlobactam in combination with other antimicrobial agents
June 11
Presenter: Alita A. Miller
#2797: Sulbactam-durlobactam is bactericidal against clinical isolates of Acinetobacter baumannii
June 11
Presenter: Sarah M. McLeod
ETX0462
Oral Presentations:
ETX0462, a novel non-β-lactam PBP inhibitor, has potent antibacterial activity against a panel of geographically diverse Gram-negative bacterial clinical isolates
Presenter: Alita A. Miller, June 10 2:45pm; Salon GHI
Poster Presentation (Poster Hall):
#3214: ETX0462, a novel non-β-lactam PBP inhibitor, does not induce AmpC expression
June 10
Presenter: Alita A. Miller
About Entasis Therapeutics Holdings Inc.
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas). For more information, visit www.entasistx.com.
Entasis Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative or plural of those terms, and similar expressions are intended to identify forward-looking statements. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, rejection of our regulatory submissions, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis’ control. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
| Company Contact | Investor Contact |
| Kyle Dow | Bruce Mackle |
| Entasis Therapeutics | LifeSci Advisors |
| (781) 810-0114 | (929) 469-3859 |
| kyle.dow@entasistx.com | bmackle@lifesciadvisors.com |
| Media Contact | |
| Brett Whelan | |
| LifeSci Communications | |
| (215) 315 3143 | |
| bwhelan@lifescicomms.com |
